INCY Forecast



Bearish<—>Bullish



80% Confidence




Bullish Case: Recent Zynyz FDA approval enhances pipeline optimism, coupled with potential Opzelura expansion boosting revenues.




Bearish Case: High operational costs, market competition, and Jakafi patent expiration in 2028 pose significant revenue risks.




Potential Outcomes:
  • Opzelura growth continues: 60% chance.
  • Competitive pressures hinder profits: 25% chance.
  • Pipeline approval delays: 15% chance.



May 20, 2025


Incyte Forecast

INCY        Incyte











Correlated Assets

Assets that tend to move strongly with INCY



PNC Forecast + Options Trading Strategies   PNC  PNC Financial Services (0.89)


KKR Forecast + Options Trading Strategies   KKR  KKR (0.88)


VB Forecast + Options Trading Strategies   VB  Vanguard Group, Inc. - Vanguard Small Cap (0.86)


EXTR Forecast + Options Trading Strategies   EXTR  Extreme Networks (0.86)


FITB Forecast + Options Trading Strategies   FITB  Fifth Third Bancorp (0.85)



Uncorrelated Assets

Assets with little price relationship to INCY



IPI Forecast + Options Trading Strategies   IPI  Intrepid Potash (-0.0)


FE Forecast + Options Trading Strategies   FE  Firstenergy (0.0)


NKE Forecast + Options Trading Strategies   NKE  Nike (0.01)


CLSK Forecast + Options Trading Strategies   CLSK  Cleanspark (0.01)


LEN Forecast + Options Trading Strategies   LEN  Lennar (0.01)



Anticorrelated Assets

Assets that tend to move strongly against INCY



EC Forecast + Options Trading Strategies   EC  Ecopetrol SA (-0.62)


PAGS Forecast + Options Trading Strategies   PAGS  PagSeguro Digital (-0.68)


UDN Forecast + Options Trading Strategies   UDN  Invesco DB US Dollar Index Bearish (-0.74)


EWW Forecast + Options Trading Strategies   EWW  iShares MSCI Mexico (-0.74)


SPDN Forecast + Options Trading Strategies   SPDN  Direxion Daily S&P 500 Bear 1X Shares (-0.82)









Become a more profitable investor with AI optimized trading strategies






×

Chat with INCY


 Ask any question about INCY!